We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.96%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$783M
AUM Growth
+$86.9M
Cap. Flow
+$43.3M
Cap. Flow %
5.53%
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.8M
3
GKOS icon
Glaukos
GKOS
+$11.5M
4
AGN
Allergan plc
AGN
+$11.2M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$13.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$11.6M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
BIIB icon
Biogen
BIIB
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Financials 1.39%
3 Technology 0.15%
4 Energy 0.13%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
101
Labcorp
LH
$25.9B
– –
-23,280
Closed -$3.08M
OCUL icon
102
Ocular Therapeutix
OCUL
$2.02B
– –
-40,000
Closed -$371K
PODD icon
103
Insulet
PODD
$9.79B
– –
-35,000
Closed -$1.8M
SUPN icon
104
Supernus Pharmaceuticals
SUPN
$2.77B
– –
-30,000
Closed -$1.29M
TMO icon
105
Thermo Fisher Scientific
TMO
$220B
– –
-25,000
Closed -$4.36M
TNDM icon
106
Tandem Diabetes Care
TNDM
$1.56B
– –
-23,400
Closed -$187K
ZBH icon
107
Zimmer Biomet
ZBH
$18.4B
– –
-92,700
Closed -$11.6M
MRTX
108
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-50,000
Closed -$183K
MTEM
109
DELISTED
Molecular Templates, Inc.
MTEM
– –
-1,221
Closed -$79K
ISEE
110
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-23,920
Closed -$61K
CNCE
111
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-30,099
Closed -$420K
ENDP
112
DELISTED
Endo International plc
ENDP
– –
-277,303
Closed -$3.1M
TTPH
113
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-15,000
Closed -$2.14M
FWP
114
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-5,226
Closed -$744K
NXTM
115
DELISTED
NxStage Medical Inc.
NXTM
– –
-213,901
Closed -$5.36M
ANTH
116
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-25,000
Closed -$41K
KITE
117
DELISTED
Kite Pharma, Inc.
KITE
– –
-60,000
Closed -$6.22M
OREX
118
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-120,000
Closed -$348K
NDRM
119
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-461,654
Closed -$13.8M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rhenman & Partners Asset Management held 120 positions worth $783M, up 12% from $696M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $43.3M of net new capital in Q3 2017, opening 12 new positions and adding to 45 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $14.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2017 buy was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.
  • Rhenman & Partners Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $12.8M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2017 reduction was Pfizer, cutting an estimated $14.2M.
  • Rhenman & Partners Asset Management fully exited NeuroDerm Ltd. Ordinary Shares in Q3 2017, selling an estimated $13.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $783M portfolio in Q3 2017.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 26 in Q3 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $783M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.